Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Apply
Optune & Temozolomide, Pembrolizumab
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step